MD960317A - Noile peptide-agoniste ale amilinei şi utilizarea lor - Google Patents

Noile peptide-agoniste ale amilinei şi utilizarea lor

Info

Publication number
MD960317A
MD960317A MD96-0317A MD960317A MD960317A MD 960317 A MD960317 A MD 960317A MD 960317 A MD960317 A MD 960317A MD 960317 A MD960317 A MD 960317A
Authority
MD
Moldova
Prior art keywords
amylin agonist
uses therefor
agonist peptides
novel amylin
novel
Prior art date
Application number
MD96-0317A
Other languages
English (en)
Russian (ru)
Inventor
Laura S. L. Gaeta
Howard Jones
Elisabeth Albrecht
Original Assignee
Anylin Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anylin Pharmaceuticals, Inc. filed Critical Anylin Pharmaceuticals, Inc.
Publication of MD960317A publication Critical patent/MD960317A/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sunt revendicaţi analogi agonişti ai amilinei şi compoziţii farmaceutice pe baza lor, procedee de tratament al diabetului şi altor stări ce necesită insulină, precum şi procedee de tratament al hipoglicemiei.
MD96-0317A 1991-11-19 1992-11-19 Noile peptide-agoniste ale amilinei şi utilizarea lor MD960317A (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79426691A 1991-11-19 1991-11-19
PCT/US1992/009842 WO1993010146A1 (en) 1991-11-19 1992-11-19 Amylin agonist peptides and uses therefor

Publications (1)

Publication Number Publication Date
MD960317A true MD960317A (ro) 1998-05-31

Family

ID=25162163

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0317A MD960317A (ro) 1991-11-19 1992-11-19 Noile peptide-agoniste ale amilinei şi utilizarea lor

Country Status (17)

Country Link
EP (2) EP1162207A1 (ro)
JP (4) JP2902115B2 (ro)
AT (1) ATE205854T1 (ro)
AU (1) AU714439B2 (ro)
CA (1) CA2100745C (ro)
CZ (1) CZ288029B6 (ro)
DE (1) DE69232064T2 (ro)
DK (1) DK0567626T3 (ro)
ES (1) ES2161697T3 (ro)
FI (1) FI118601B (ro)
GR (1) GR3036794T3 (ro)
HK (1) HK1041891A1 (ro)
MD (1) MD960317A (ro)
NO (2) NO324405B1 (ro)
RU (1) RU2130463C1 (ro)
SK (1) SK88793A3 (ro)
WO (1) WO1993010146A1 (ro)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
DE69426304T2 (de) 1993-09-07 2001-03-15 Amylin Pharmaceuticals Inc Methoden zur regulation der den magen und darm betreffenden motilitaet
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
ATE410182T1 (de) * 1998-01-09 2008-10-15 Amylin Pharmaceuticals Inc Formulierungen für amylin peptidagonisten mit insulin
GB0128583D0 (en) 2001-11-28 2002-01-23 Rsr Ltd Detection of autoantibodies indicative of diabetes
WO2004037168A2 (en) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004083243A1 (en) * 2003-03-18 2004-09-30 Applied Research Systems Ars Holding N.V. Amylin aggregation inhibitors and use thereof.
EP1807442A1 (en) * 2004-10-26 2007-07-18 Lonza Ag S-alkyl-sulphenyl protection groups in solid-phase synthesis
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
EA013121B1 (ru) 2005-03-31 2010-02-26 Амилин Фармасьютикалз, Инк. Амилин и агонисты амилина для лечения психиатрических заболеваний и расстройств
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP2010502670A (ja) 2006-09-07 2010-01-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 真性糖尿病のための組合せ治療
EP2120985B1 (en) 2007-02-05 2012-06-27 Amylin Pharmaceuticals, Inc. FN-38 peptides for use in the treatment of psychotic and anxiety disorders
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
KR101673042B1 (ko) 2009-03-12 2016-11-04 키바이오사이언스 아게 당뇨병 및 대사 증후군의 치료
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
CA2928725A1 (en) 2013-11-05 2015-05-14 Esther Priel Compounds for the treatment of diabetes and disease complications arising from same
DK3137494T3 (da) * 2014-05-02 2021-10-04 Univ New York State Res Found Isletamyloidpolypeptider med forbedret opløselighed
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
KR102130354B1 (ko) * 2019-08-14 2020-07-06 엘아이지넥스원 주식회사 코어 제거용 이형장치
AU2023278353A1 (en) 2022-05-30 2024-05-23 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
WO1989006135A1 (en) * 1988-01-11 1989-07-13 Amylin Corporation Treatment of type 2 diabetes mellitus
WO1991000737A1 (en) * 1989-07-10 1991-01-24 Amylin Corporation Treatment of obesity and essential hypertension and related disorders
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
WO1992015317A1 (en) * 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues

Also Published As

Publication number Publication date
CZ168993A3 (en) 1994-04-13
CA2100745C (en) 2007-07-31
HK1041891A1 (zh) 2002-07-26
EP0567626A1 (en) 1993-11-03
JP2003238594A (ja) 2003-08-27
DE69232064D1 (de) 2001-10-25
DK0567626T3 (da) 2001-12-17
NO932603D0 (no) 1993-07-19
JP2006213716A (ja) 2006-08-17
JP2902115B2 (ja) 1999-06-07
NO324405B1 (no) 2007-10-08
JPH06504794A (ja) 1994-06-02
AU1245697A (en) 1997-03-27
ATE205854T1 (de) 2001-10-15
ES2161697T3 (es) 2001-12-16
AU3075392A (en) 1993-06-15
EP1162207A1 (en) 2001-12-12
GR3036794T3 (en) 2002-01-31
CA2100745A1 (en) 1993-05-20
JPH11152299A (ja) 1999-06-08
NO20073265L (no) 1993-09-17
FI933252A (fi) 1993-08-23
RU2130463C1 (ru) 1999-05-20
AU714439B2 (en) 2000-01-06
FI933252A0 (fi) 1993-07-16
WO1993010146A1 (en) 1993-05-27
JP4018116B2 (ja) 2007-12-05
CZ288029B6 (cs) 2001-04-11
FI118601B (fi) 2008-01-15
SK88793A3 (en) 1994-12-07
DE69232064T2 (de) 2002-03-28
NO932603L (no) 1993-09-17
EP0567626B1 (en) 2001-09-19
AU673147B2 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
MD960317A (ro) Noile peptide-agoniste ale amilinei şi utilizarea lor
AP2000001888A0 (en) Method for treatment of diabetes using peptides analogues of insulin.
AU3173297A (en) Exendin analogues, processes for their preparation and medicaments containing them
AU3372595A (en) Biologically active fragments of glucagon-like insulinotropic peptide
DE68929217D1 (en) Insulinotropes hormon
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
IL112112A (en) Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
ATE273996T1 (de) Zusammensetzung zur therapie von diabetes mellitus und fettsucht
RU93053497A (ru) Новые пептиды-агонисты и их использование
EP0833912A4 (en) NEW TRANSFORMING GROWTH FACTOR TYPE CYTOKINE TGF-BETA
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MD1652G2 (ro) Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină
DE3466879D1 (en) Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
PL321091A1 (en) Analogues of peptide p@&& and pharmaceutic sets of components containing them, used in treatment or diagnosis of diabetes
ES8507473A1 (es) Un procedimiento para preparar un peptido de resina
AU548677B2 (en) Peptides derived from glucagon
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
MY106352A (en) Hemoregulatory peptides.
EP0362520A3 (de) Ein neues Antibiotikum, Mersacidin, ein Verfahren zur seiner Herstellung und seine Verwendung als Arzneimittel
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
UA27771C2 (uk) Електролітична комірка (варіанти) та спосіб мічення протеїнів, пептидів і інших органічних молекул
UA27142C2 (uk) Фармацевтичhа композиція
RU95106486A (ru) Аналоги амилина, способы лечения сахарного диабета типа i и ii и гипергликемии, способ регулирования принятия пищи